Here is the design of a clinical trial:

Official Title: Non-Opioid Prescriptions After Arthroscopic Surgery in Canada (NO PAin): a Randomized Controlled Trial

Included conditions:
- Knee Arthroscopy
- Shoulder Arthroscopy

Study Armgroups:
- {'label': 'Non-Opioid Prescription and Infographic', 'type': 'ACTIVE_COMPARATOR', 'description': 'The study intervention will involve 3 components:\n\n1. A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 20mg PO daily x 30 tabs (to be taken only while utilizing Naproxen). In the case of a Naproxen intolerance, a prescription for Meloxicam 15mg PO BID PRN x 60 tabs will be given.\n2. A limited opioid "rescue prescription": A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.\n3. Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control.', 'interventionNames': ['Combination Product: Non-Opioid Prescription and Infographic']}
- {'label': 'Standard of Care', 'type': 'OTHER', 'description': 'The control group is standard of care, which typically includes a prescription for an opioid.', 'interventionNames': ['Combination Product: Non-Opioid Prescription and Infographic']}

Interventions:
- {'type': 'COMBINATION_PRODUCT', 'name': 'Non-Opioid Prescription and Infographic', 'description': 'The study intervention will involve 3 components:\n\n1. A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 40mg PO daily x 30 tabs (to be taken only while utilizing Naproxen).\n2. A limited opioid "rescue prescription": A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.\n3. Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control.', 'armGroupLabels': ['Non-Opioid Prescription and Infographic', 'Standard of Care']}

Primary Outcomes:
- {'measure': 'Total oral morphine equivalents (OMEs)', 'description': 'The primary outcome is the number of total OMEs consumed as determined by a patient-reported medication diary.', 'timeFrame': '6 weeks postoperatively'}

Please estimate the sample size based on the assumption: 
Alpha-value of 0.05, power of 80%, and a standard deviation of 155 OMEs. Sample sizes should be increased by 10-40% to account for loss to follow-up and unforeseen circumstances.
Sample size calculation
        Based on prior literature, patients undergoing knee and shoulder arthroscopy can be expected to consume a median of about 100 OMEs post-surgery without intervention [4]. We are prescribing 75 OMEs in the intervention group with a rescue opioid prescription. Patients have been shown to consume 25â50% of their prescription depending on whether they are undergoing knee or shoulder arthroscopy, respectively. Given this, we expect that the overall prescription consumption will be 33% of the prescribed amount (i.e. 25 OMEs). Using an alpha-value of 0.05, power of 80%, and a standard deviation of 155 OMEs [4], the required sample size is 68 patients per group, for a total sample size of 136. According to Thoma et al., estimated sample sizes should be increased by 10â40% to allow for loss to follow-up and unforeseen circumstances [27]. Thus, based on the most conservative estimate of this guidance, we will increase our sample size by 40% for a total of 190 patients, rounded to 200 (100 per group). Allowing for patients who need to be excluded, those who choose not to participate, and loss to follow-up, we estimate we will need to screen approximately 300 patients for eligibility for a 66% inclusion rate [28].